BAP1 and meningioma: WHO identifies numerous molecular markers associated with specific subtypes, such as loss of nuclear SMARCE1 expression in clear cell meningiomas,BAP1mutations and loss of BAP1 staining in rhabdoid and papillary subtypes,KLF4/TRAF7alterations in secretory meningiomas, as well asTERTpromoter mutations orCDKN2A/Bhomozygous deletions in anaplastic tumors.